News

On May 20, 2023, Beicell Therapeutics launched the "Human Chemical Reprogramming Induced Pluripotent Stem Cell Kit" for the first time at the Second Forum of Peking University Third Hospital. The kit is based on the latest breakthrough achievement of the team of Professor Deng Hongkui of Peking University "Using chemical small molecules to induce human adult cells to transform into pluripotent stem cells (Nature, 2022; Cell Stem Cell, 2023)", which can stably and efficiently transform human adult fat The derived stromal cells (ADSC) and skin fibroblasts (Fibroblast) were reprogrammed into human chemically induced pluripotent stem cells (human CiPS cells). Once the kit was launched, it received widespread attention.

In order to introduce better products and technologies and promote industry innovation, ACROBiosystems pays close attention to industry trends and actively communicates and interacts with partners through the ACRO Partnering model. It is reported that at the beginning of this month, the Aneuro team, a sub-brand of ACROBiosystems, used the human chemical reprogramming kit of Beicell Therapeutics to prepare primary human CiPS cells. The cells have a typical pluripotent stem cell morphology and express core pluripotency genes such as OCT4 and NANOG (see image below). This is also the first time that the kit has been independently repeated by a third party after its launch.

Morphology of human CiPS cells and expression of core pluripotency genes OCT4 and NANOG induced by human chemical reprogramming kit

Dr. Qi Zhen, Head of Aneuro Stem Cell R&D at ACROBiosystems, said, "With the mission of accelerating the development and marketing of biological drugs, we pay close attention to the frontier trends. Once Beicell's human chemical reprogramming-induced pluripotent stem cell kit was launched, we cooperated with Deng Hongkui The professor's team actively communicates. The team's human chemical reprogramming kit has achieved good results in our experiments. The kit is easy to use, and we can use it in less than one and a half months through simple technical exchanges The kit successfully induced primary human CiPS cells, indicating that the chemical reprogramming technology is advanced, easy to operate, and reproducible."

Introduction to ACROBiosystems

ACROBiosystems Group (stock code: 301080) is a multinational biotechnology company established in 2010. It is an industry platform cornerstone enterprise that provides key biological reagent products and solutions for the global biomedicine and health industries. It will be listed on the GEM in 2021. The business of Baipsies Group is all over the world, spanning Asia, North America, and Europe. It has offices, R&D centers, and production bases in 12 cities including China, the United States, and Switzerland. It has served more than 8,000 customers in total and has established long-term and stable partnerships with global Top 20 pharmaceutical companies. The group owns brands such as ACROBiosystems, bioSeedin, Condense Capital, and ACRODiagnostics.

ACRO Partnering is committed to creating an ecosystem integrating life science tools, reagents, and instruments. ACROBiosystems is willing to join hands with the whole industry and is willing to cooperate with commercial companies, research institutions, and entrepreneurial teams to commercialize new technologies that are now mature or that can be improved in the next 3-5 years, and jointly serve the global Growing customer groups such as pharmaceutical companies, CRO/CDMO, research institutions, and hospitals.

Aneuro is a sub-brand of ACROBiosystems, serving the R&D and marketing of biological drugs in the field of brain and nerve. Its representative products include Tau, APP, BACE1, Alpha-Synuclein, LRRK2, DDC, HTT, SOD1, CD20, ITGA4, IFNAR1, S1PR5, VEGF, EGFR, mTORC1, and other target proteins and prefabricated precursor fibers (PFFs), which can be used in Treatment research and drug development for brain nerve-related diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, and brain tumors.